➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
McKinsey
Moodys
Colorcon
Boehringer Ingelheim
Johnson and Johnson

Last Updated: September 25, 2020

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 212809

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

NDA 212809 describes CAPTOPRIL, which is a drug marketed by Ajanta Pharma Ltd, Apothecon, Boscogen, Corepharma, Cosette, Dava Pharms Inc, Egis Pharms, G And W Labs Inc, Hikma Intl Pharms, Mylan, Oxford Pharms, Par Pharm, Prinston Inc, Purepac Pharm, Sandoz, Seton Pharms, Teva, Watson Labs, Wockhardt Ltd, Yaopharma Co Ltd, Ivax Sub Teva Pharms, and Vintage Pharms Llc, and is included in thirty NDAs. It is available from thirteen suppliers. Additional details are available on the CAPTOPRIL profile page.

The generic ingredient in CAPTOPRIL is captopril; hydrochlorothiazide. There are fifteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the captopril; hydrochlorothiazide profile page.
Summary for 212809
Tradename:CAPTOPRIL
Applicant:Ajanta Pharma Ltd
Ingredient:captopril
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 212809
Medical Subject Heading (MeSH) Categories for 212809
Suppliers and Packaging for NDA: 212809
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
CAPTOPRIL captopril TABLET;ORAL 212809 ANDA Ajanta Pharma Limited 27241-160 27241-160-01 100 TABLET in 1 BOTTLE (27241-160-01)
CAPTOPRIL captopril TABLET;ORAL 212809 ANDA Ajanta Pharma Limited 27241-160 27241-160-10 1000 TABLET in 1 BOTTLE (27241-160-10)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength12.5MG
Approval Date:Dec 13, 2019TE:ABRLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength25MG
Approval Date:Dec 13, 2019TE:ABRLD:No

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength50MG
Approval Date:Dec 13, 2019TE:ABRLD:No

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
McKinsey
Mallinckrodt
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.